Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4

This study examined whether therapy with a non-mitogenic, non-activating an ti-CD3 mAb (G4.18) alone, or in combination with the T(h)2 cytokines, could inhibit induction or facilitate recovery from experimental allergic enceph alomyelitis (EAE) in Lewis rats. G4.18, but not rIL-4, rIL-5 or anti-IL-4 m Ab, reduced the severity and accelerated recovery from active EAE. A combin ation of rIL-4 with G4.18 was more effective than G4.18 alone. The infiltra te of CD4(+) and CD8(+) T cells, B cells, dendritic cells, and macrophages in the brain stem was less with combined G4.18 and IL-4 than G4.18 therapy or no treatment. Residual cells had preferential sparing of T(r)1 cytokines IL-5 and transforming growth factor-beta with loss of T(h)1 markers IL-2, IFN-gamma and IL-12R beta2, and the T(h)2 cytokine IL-4 as well as macropha ge cytokines IL-10 and tumor necrosis factor-alpha. Lymph nodes draining th e site of immunization had less mRNA for TO cytokines, but T(h)2 and T(r)1 cytokine expression was spared. Treatment with G4.18, rIL-4 or rIL-5 from t he time of immunization had no effect on the course of active EAE. MRC OX-8 1, a mAb that blocks IL-4, delayed onset by 2 days, but had no effect on se verity of active EAE. G4.18 also inhibited the ability of activated T cells from rats with active EAE to transfer passive EAE. This study demonstrated that T cell-mediated inflammation was rapidly reversed by a non-activating anti-CD3 mAb that blocked effector T(h)1 cells, and spared cells expressin g T(h)2 and T(r)1 cytokines.